BEAM – beam therapeutics inc. (US:NYSE)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Days Volatility
Open
Prior Close

YTD

1 Day

BEAM

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

2/25

10:24 am

beam

Beam Therapeutics (BEAM) had its price target raised by Royal Bank Of Canada from $22.00 to $26.00. They now have a "sector perform" rating on the stock.

Medium Report

Beam Therapeutics (BEAM) had its price target raised by Royal Bank Of Canada from $22.00 to $26.00. They now have a "sector perform" rating on the stock.

Report

2/25

08:42 am

beam

Beam Therapeutics (BEAM) had its price target raised by Wedbush from $57.00 to $65.00. They now have an "outperform" rating on the stock.

Medium Report

Beam Therapeutics (BEAM) had its price target raised by Wedbush from $57.00 to $65.00. They now have an "outperform" rating on the stock.

Report

2/25

07:22 am

beam

Beam Therapeutics Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]

Medium Report

Beam Therapeutics Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]

Report

2/24

10:56 am

beam

Beam Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]

Medium Report

Beam Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]

Report

2/24

07:01 am

beam

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Medium Report

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Report

2/24

07:00 am

beam

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

High Report

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Report

2/23

07:05 pm

beam

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program [Yahoo! Finance]

High Report

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program [Yahoo! Finance]

Report

2/23

04:00 pm

beam

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

High Report

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

Report

Date

Time

Symbol

Company Name

Action

%Chg

2/24/2026

07:01 am

BEAM

beam therapeutics inc.

BEAT Report

9.3%

beam therapeutics inc.

Report

11/4/2025

07:00 am

BEAM

beam therapeutics inc.

MISS Report

-3.7%

beam therapeutics inc.

Report

8/5/2025

07:00 am

BEAM

beam therapeutics inc.

BEAT Report

-2.1%

beam therapeutics inc.

Report

5/6/2025

07:00 am

BEAM

beam therapeutics inc.

MISS Report

-18.6%

beam therapeutics inc.

Report

Date

Time

Action

From

Firm

Impact

%Chg

2/25

10:10 am

Maintains

Sector Perform

RBC Capital

High

Report

-10.1%

Report

2/25

10:10 am

Maintains

Sector Perform

RBC Capital

High

Report

-10.1%

Report

2/25

08:23 am

Maintains

Outperform

Wedbush

Medium

Report

-9.4%

Report

2/25

08:23 am

Maintains

Outperform

Wedbush

Medium

Report

-9.4%

Report

2/20

03:50 pm

Initiates

Buy

Canaccord Genuity

Low

Report

0.3%

Report

2/20

06:51 am

Initiates

BUY

CANACCORD

Medium

Report

-3.2%

Report

2/20

06:29 am

Initiates

BUY

CANACCORD

Low

Report

-2.0%

Report

1/21

10:11 am

Maintains

Outperform

Bernstein

Low

Report

0.4%

Report

Date

Time

Symbol

Headline

Impact

2/24

04:16 pm

beam

Form 144 Beam Therapeutics Inc. Filed by: Ciaramella Giuseppe

Medium Report

Form 144 Beam Therapeutics Inc. Filed by: Ciaramella Giuseppe

Report

2/24

07:23 am

beam

Form S-8 Beam Therapeutics Inc.

High Report

Form S-8 Beam Therapeutics Inc.

Report

2/24

07:11 am

beam

Form 10-K Beam Therapeutics Inc. For: Dec 31

Medium Report

Form 10-K Beam Therapeutics Inc. For: Dec 31

Report

2/24

07:06 am

beam

Form 8-K Beam Therapeutics Inc. For: Feb 24

Medium Report

Form 8-K Beam Therapeutics Inc. For: Feb 24

Report

2/12

04:06 pm

beam

Form 8-K Beam Therapeutics Inc. For: Feb 09

Medium Report

Form 8-K Beam Therapeutics Inc. For: Feb 09

Report

2/9

06:19 am

beam

Form SCHEDULE 13G Beam Therapeutics Inc. Filed by: STATE STREET CORP

Low Report

Form SCHEDULE 13G Beam Therapeutics Inc. Filed by: STATE STREET CORP

Report

2/5

04:06 pm

beam

Form 8-K Beam Therapeutics Inc. For: Jan 31

Medium Report

Form 8-K Beam Therapeutics Inc. For: Jan 31

Report

2/5

02:57 pm

beam

Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: Farallon Capital Partners, L.P.

Low Report

Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: Farallon Capital Partners, L.P.

Report

Stock Stats

News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings

Order Stats
Sub-Penny

Odd lot

Avg. bid-ask spread

Avg. bid-ask size

Shares at ask/bid

Off exchange

Main News & Impact Reports

Don’t Miss Out On The Next BIG Stock Move

Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.